A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

Squamous Cell Carcinoma of the Head and Neck Clinical Trial

Official title:

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05459129
• Other study ID #: CO43613
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: April 13, 2023
• Est. completion date: August 11, 2024

Study information

• Verified date: June 2024
• Source: Hoffmann-La Roche
• Contact: Reference Study ID Number: CO43613 https://forpatients.roche.com
• Phone: 888-662-6728 (U.S. and Canada)
• Email: global-roche-genentech-trials[@]gene.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with locally advanced squamous cell carcinoma of the head and neck (SCCHN). The study will enroll treatment-naive participants with resectable Stage III-IVA human papillomavirus (HPV)-negative, programmed death-ligand 1 (PD-L1)-positive SCCHN with measurable disease, as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) who have not received systemic treatment for their disease.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: August 11, 2024
• Est. primary completion date: August 11, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Eastern Cooperative Oncology Group Performance Status of 0 or 1

• Histologically confirmed, resectable Stage III-IVA SCCHN

• Eligible candidate for R0 resection with curative intent at the time of screening

• HPV-negative test for oropharyngeal carcinoma, as determined locally by p16 immunohistochemistry (IHC), in situ hybridization, or polymerase chain reaction-based assay

• Measurable disease (at least one target lesion), as assessed according to RECIST v1.1

• PD-L1 expression, defined as a combined positive score (CPS) >= 1

• Adequate hematologic and end-organ function

• Negative HIV test with the following exception: patients with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy, have a CD4 count >= 200/µL, and have an undetectable viral load.

• Negative hepatitis B surface antigen (HBsAg) test at screening

• Positive hepatitis B surface antibody (HBsAb) test at screening, or negative HBsAb at screening accompanied by either of the following: Negative total hepatitis B core antibody (HBcAb), Positive total hepatitis B core antibody (HBcAb) followed by a negative quantitative hepatitis B virus (HBV) DNA.

Exclusion Criteria:

• HPV-positive oropharyngeal cancer, as determined locally by p16 IHC, in situ hybridization, or by polymerase chain reactions-based assay

• Distantly metastasized SCCHN

• Any prior therapy for SCCHN, including immunotherapy, chemotherapy, or RT

• Prior treatment with any of the protocol-specified study treatments

• Treatment with investigational therapy within 42 days prior to initiation of study treatment

• Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment

• Prior allogeneic stem cell or solid organ transplantation

• Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment

• Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during study treatment or within 5 months after the final dose of study treatment

• Active or history of autoimmune disease or immune deficiency

• History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT scan)

• History of malignancy other than SCCHN within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5 -year OS rate>90%)

• Active tuberculosis

• Severe infection within 4 weeks prior to initiation of study treatment

• Treatment with therapeutic or prophylactic oral or intravenous (IV) antibiotics within 2 weeks prior to initiation of study treatment

• Significant cardiovascular disease such a New York Heart Association cardiac disease (Class II or greater), myocardial infarction or cerebrovascular accident within 3 months prior to initiation of study treatment, unstable arrhytmia, or unstable angina

• Major surgical procedure, other than for diagnosis, within 4 weeks prior to study initiation of study treatment, or anticipation of need for a major surgical procedure other than tumor resection, during the study

• Any of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of investigational drug, may affect the interpretation of the results, impair the ability of the patient to participate in the study, or renders the patient at high risk form treatment complications

• History of severe allergic reactions to chimeric or humanized antibodies or fusion proteins

• Known hypersensitivity to Chinese hamster ovary cell products or recombinant human antibodies

• Known allergy or hypersensitivity to any of the study drugs or their excipients

• Known intolerance to any of the drugs required for premedication

• Pregnancy or breastfeeding, or intention of becoming pregnant during the study

• Eligible only for the control arm

• Active EBV infection or known or suspected chronic EBV infection at screening

Specific Exclusion Criteria for Atezo+Tira+CP:

• Known severe allergy or hypersensitivity to placlitaxel, platinum or platinum-containing compounds

• Known history of severe hypersensitivity to products containing Cremophor EL

• Creatinine clearance <45m./min (Calculated using the Cockcroft-Gault formula)

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Head and Neck Neoplasms
• Squamous Cell Carcinoma of Head and Neck
• Squamous Cell Carcinoma of the Head and Neck

Intervention

Drug:
• Atezolizumab
Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
• Tiragolumab
Tiragolumab will be administered intravenously at a fixed dose of 600 mg on Day 1 of each 21-day cycle.
• Carboplatin
Carboplatin will be administered intravenously at a dose of area under the concentration-time curve (AUC) 5 mg/mL/min on Day 1 of each 21 day cycle.
• Paclitaxel
Paclitaxel will be administered intravenously at a dose of 175 mg/m2 on Day 1 of each 21 day cycle.

Locations

Country	Name	City	State
Australia	Cancer Research SA	Adelaide	South Australia
Australia	Sir Charles Gairdner Hospital; Medical Oncology	Perth	Western Australia
France	Centre Francois Baclesse	Caen
France	CHU Hopitaux de Bordeaux	CHU Hopitaux De Bordeaux
France	Centre Georges François Leclerc; Service Pharmacie, Bp 77980	Dijon
France	Centre Léon Bérard	Lyon
France	INSTITUT CURIE_SITE PARIS - Service d'Oncologie Médicale.	St Cloud
France	Institut de Cancérologie de Lorraine	Vandoeuvre-Les-Nancy
Israel	Rambam Medical Center	Haifa
Israel	Hadassah University Hospital - Ein Kerem; Oncology	Jerusalem
Korea, Republic of	Asan Medical Center	Seoul
Korea, Republic of	Severance Hospital - Yonsei Cancer Center	Seoul
Spain	Vall d?Hebron Institute of Oncology (VHIO), Barcelona; Servicio de Farmacia. Semi-sótano USIFO	Barcelona
Spain	Institut Catala d Oncologia Hospitalet	Hospitalet de Llobregat	Barcelona
Spain	Hospital Clínico San Carlos; Oncology Service	Madrid
Spain	Hospital Clinico Universitario de Valencia	Valencia
Spain	Hospital Universitario La Fe	Valencia
Switzerland	Universitätsspital Basel (USB)	Basel
United Kingdom	Beatson West of Scotland Cancer Centre	Glasgow
United States	University of Michigan Comprehensive Cancer Center	Ann Arbor	Michigan
United States	Winship Cancer Institute	Atlanta	Georgia
United States	N.C. Cancer Hospital	Chapel Hill	North Carolina
United States	City of Hope	Duarte	California
United States	UCLA Jonsson Comprehensive Cancer Center	Los Angeles	California
United States	Medical College of Wisconsin	Milwaukee	Wisconsin
United States	Thomas Jefferson University Hospital	Philadelphia	Pennsylvania
United States	University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania
United States	Providence Portland Medical Center	Portland	Oregon
United States	The George Washington Cancer Center	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Hoffmann-La Roche

Countries where clinical trial is conducted

United States,  Australia,  France,  Israel,  Korea, Republic of,  Spain,  Switzerland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pathologic Complete Response (pCR), as Determined by Local Pathologic Review	pCR is defined as the absence of any viable primary tumor at time of surgical resection, as determined by local pathologic review.	At the time of surgery
Secondary	Pathologic Response Rate (pRR), as Determined by Local Pathologic Review	pRR is defined as the proportion of participants with a pCR, mPR (defined as <=10% residual viable tumor at the time of surgical resection in the primary tumor) and pPR (defined as <=50% residual viable tumor at the time of surgical resection in the primary tumor).	At the time of surgery
Secondary	Event-Free Survival (EFS)	EFS is defined as the time from randomization to any of the following events (whichever occurs first): disease progression that precludes surgery, as determined by the investigator according to RECIST v1.1, local, regional, or distant disease recurrence, or death from any cause.	Randomization up to approximately 5 years
Secondary	Relapse-Free Survival (RFS)	RFS is defined as the time from surgery to the first documented recurrence of disease or death from any cause.	Surgery up to approximately 5 years
Secondary	Overall Survival (OS)	OS is defined as the time from randomization to death from any cause.	Randomization up to approximately 5 years
Secondary	Objective Response Rate (ORR)	ORR is defined as the proportion of patients with a complete response or a partial response, as determined by the investigator according to RECIST v1.1, prior to surgery.	After completion of neoadjuvant treatment
Secondary	Percentage of Participants With Adverse Events	Percentage of participants with adverse events.	Up to 5 years after first participant enrolled
Secondary	Percentage of Participants with Immune-Related Adverse Events Grade >=3	Percentage of immune-related adverse events Grade >=3	Up to Week 12 after first participant enrolled
Secondary	Rate of Delayed Surgery Due to Treatment-Related Adverse Events	Percentage of participants with >=2 weeks delay in surgery from planned surgery due to treatment-related adverse events.	>=2 weeks delay from the planned surgery
Secondary	Duration of Delayed Surgery Due to Treatment-Related Adverse Events	Duration of delay defined as time from planned surgery to the actual surgery date.	>=2 weeks delay from the planned surgery
Secondary	Surgical Complication Rates	Surgical complications will be scored according to Clavien-Dindo classification.	From surgery through follow-up (up to approximately 5 years)
Secondary	Landmark EFS	Landmark EFS is defined as the time from randomization to any of the following events (whichever occurs first): disease progression that precludes surgery, as determined by the investigator according to RECIST v1.1; local, regional, or distant disease recurrence; or death from any cause at specified timepoints (1, 2, 3, and 5 years)	Randomization to specified timepoints (1, 2, 3, and 5 years)
Secondary	Landmark RFS	Landmark RFS is defined as the time from surgery to the first documented recurrence of disease or death from any cause at specified timepoints (1, 2, 3, and 5 years)	From surgery to specified timepoints (1, 2, 3, and 5 years)
Secondary	Landmark OS	Landmark OS is defined as the time from randomization to death from any cause at specified timepoints (1, 2, 3, and 5 years)	Randomization to specified timepoints (1, 2, 3, and 5 years